Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2018
New life-extending lung cancer treatment approved by NICE
22 November 2018 - NICE today recommends in draft guidance that immunotherapy drug pembrolizumab (also known as Keytruda), used with ...
Posted by Michael Wonder on 19 Nov 2018
Innovative skin cancer drug available on Cancer Drugs Fund
19 November 2018 - Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known ...
Posted by Michael Wonder on 15 Nov 2018
Final NICE green light for Pfizer’s Mylotarg
15 November 2018 - Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, ...
Posted by Michael Wonder on 13 Nov 2018
ICR responds to NICE decision on olaparib for women with advanced ovarian cancer
9 November 2018 - NICE has announced today its decision not to recommend olaparib for women with advanced ovarian cancer ...
Posted by Michael Wonder on 12 Nov 2018
Availability of Orkambi on the NHS
9 November 2018 - The Health and Social Care Committee has formally requested documents from Vertex Pharmaceuticals, NHS England and ...
Posted by Michael Wonder on 10 Nov 2018
NICE says no to expanding use of AstraZeneca's’ Lynparza
9 November 2018 - NICE has ruled against expanding use of AstraZeneca’s Lynparza to a wider patient population with ovarian ...
Posted by Michael Wonder on 09 Nov 2018
Lenvima backed for NHS use to treat liver cancer
9 November 2018 - NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and ...
Posted by Michael Wonder on 09 Nov 2018
NICE nod for Jazz’ AML chemo
8 November 2018 - Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of NICE for routine use on the NHS ...
Posted by Michael Wonder on 29 Oct 2018
NICE turns down hyperkalaemia therapies
29 October 2018 - Preliminary guidelines released by the NICE do not recommend NHS funding for hyperkalaemia treatments Lokelma and ...
Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 19 Oct 2018
NICE rejects Lilly’s breast cancer drug Verzenios
19 October 2018 - As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast ...
Posted by Michael Wonder on 18 Oct 2018
NHS green light for Novartis skin cancer combo
18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available ...
Posted by Michael Wonder on 10 Oct 2018
XLH patients to get routine access to first new therapy in 30 years
10 October 2018 - For the first time in more than 30 years children and young adults in England and ...
Posted by Michael Wonder on 08 Oct 2018
NICE expands backing for Pfizer’s Mylotarg
8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with ...
Posted by Michael Wonder on 05 Oct 2018
Gilead strikes deal with NHS England on CAR-T Yescarta
5 October 2018 - NHS England claims adult leukaemia access is first in Europe. ...